Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.

Tkaczyk C, Kasturirangan S, Minola A, Jones-Nelson O, Gunter V, Shi YY, Rosenthal K, Aleti V, Semenova E, Warrener P, Tabor D, Stover CK, Corti D, Rainey G, Sellman BR.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00629-17. doi: 10.1128/AAC.00629-17. Print 2017 Aug.

2.

Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.

Liu B, Park S, Thompson CD, Li X, Lee JC.

Virulence. 2017 Aug 18;8(6):859-874. doi: 10.1080/21505594.2016.1270494. Epub 2016 Dec 9.

3.

Lessons from the Crystal Structure of the S. aureus Surface Protein Clumping Factor A in Complex With Tefibazumab, an Inhibiting Monoclonal Antibody.

Ganesh VK, Liang X, Geoghegan JA, Cohen ALV, Venugopalan N, Foster TJ, Hook M.

EBioMedicine. 2016 Nov;13:328-338. doi: 10.1016/j.ebiom.2016.09.027. Epub 2016 Oct 1.

4.

Staphylococcus aureus Aggregation and Coagulation Mechanisms, and Their Function in Host-Pathogen Interactions.

Crosby HA, Kwiecinski J, Horswill AR.

Adv Appl Microbiol. 2016;96:1-41. doi: 10.1016/bs.aambs.2016.07.018. Epub 2016 Aug 4. Review.

5.

Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection.

Anderson AS, Scully IL, Buurman ET, Eiden J, Jansen KU.

MBio. 2016 Mar 8;7(2):e00225. doi: 10.1128/mBio.00225-16.

6.

Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.

Yang Y, Qian M, Yi S, Liu S, Li B, Yu R, Guo Q, Zhang X, Yu C, Li J, Xu J, Chen W.

PLoS One. 2016 Feb 29;11(2):e0149460. doi: 10.1371/journal.pone.0149460. eCollection 2016.

7.

Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia models.

Yang L, Cai C, Feng Q, Shi Y, Zuo Q, Yang H, Jing H, Wei C, Zhuang Y, Zou Q, Zeng H.

Sci Rep. 2016 Feb 11;6:20929. doi: 10.1038/srep20929.

8.

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ.

Trends Pharmacol Sci. 2016 Mar;37(3):231-41. doi: 10.1016/j.tips.2015.11.008. Epub 2015 Dec 22. Review.

9.

Investigational drugs to treat methicillin-resistant Staphylococcus aureus.

Vuong C, Yeh AJ, Cheung GY, Otto M.

Expert Opin Investig Drugs. 2016;25(1):73-93. doi: 10.1517/13543784.2016.1109077. Epub 2015 Nov 4. Review.

10.

Wall teichoic acids prevent antibody binding to epitopes within the cell wall of Staphylococcus aureus.

Gautam S, Kim T, Lester E, Deep D, Spiegel DA.

ACS Chem Biol. 2016 Jan 15;11(1):25-30. doi: 10.1021/acschembio.5b00439. Epub 2015 Nov 5.

11.

Successful selection of an infection-protective anti-Staphylococcus aureus monoclonal antibody and its protective activity in murine infection models.

Ohsawa H, Baba T, Enami J, Hiramatsu K.

Microbiol Immunol. 2015 Apr;59(4):183-92. doi: 10.1111/1348-0421.12242.

12.

In silico analysis for identifying potential vaccine candidates against Staphylococcus aureus.

Delfani S, Imani Fooladi AA, Mobarez AM, Emaneini M, Amani J, Sedighian H.

Clin Exp Vaccine Res. 2015 Jan;4(1):99-106. doi: 10.7774/cevr.2015.4.1.99. Epub 2015 Jan 30.

13.

Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants.

Brady RA, Mocca CP, Burns DL.

Clin Vaccine Immunol. 2013 Aug;20(8):1338-40. doi: 10.1128/CVI.00275-13. Epub 2013 Jun 26.

14.

Will there ever be a universal Staphylococcus aureus vaccine?

Pier GB.

Hum Vaccin Immunother. 2013 Sep;9(9):1865-76. doi: 10.4161/hv.25182. Epub 2013 Jun 21. Review.

15.

Two Dimensional Structural Analysis and Expression of a New Staphylococcus aureus Adhesin Based Fusion Protein.

Faghri J, Shahbazzadeh D, Pooshang Bagheri K, Moghim S, Ghasemian Safaei H, Nasr Esfahani B, Fazeli H, Yazdani R, Mirmohammad Sadeghi H.

Iran J Basic Med Sci. 2012 Mar;15(2):725-38.

16.

Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia.

Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E, Höök M, Degen JL.

Blood. 2013 Mar 7;121(10):1783-94. doi: 10.1182/blood-2012-09-453894. Epub 2013 Jan 8.

17.

Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.

Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB.

PLoS One. 2012;7(10):e46648. doi: 10.1371/journal.pone.0046648. Epub 2012 Oct 15.

18.

Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.

Maira-Litrán T, Bentancor LV, Bozkurt-Guzel C, O'Malley JM, Cywes-Bentley C, Pier GB.

PLoS One. 2012;7(9):e43813. doi: 10.1371/journal.pone.0043813. Epub 2012 Sep 6.

19.

A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.

Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG.

Clin Vaccine Immunol. 2012 Oct;19(10):1641-50. Epub 2012 Aug 15.

20.

Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.

Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR.

Clin Vaccine Immunol. 2012 Mar;19(3):377-85. doi: 10.1128/CVI.05589-11. Epub 2012 Jan 11.

Supplemental Content

Support Center